» Articles » PMID: 36408523

An MRI-based Joint Model of Radiomics and Spatial Distribution Differentiates Autoimmune Encephalitis from Low-grade Diffuse Astrocytoma

Overview
Journal Front Neurol
Specialty Neurology
Date 2022 Nov 21
PMID 36408523
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The differential diagnosis between autoimmune encephalitis and low-grade diffuse astrocytoma remains challenging. We aim to develop a quantitative model integrating radiomics and spatial distribution features derived from MRI for discriminating these two conditions.

Methods: In our study, we included 188 patients with confirmed autoimmune encephalitis ( = 81) and WHO grade II diffuse astrocytoma ( = 107). Patients with autoimmune encephalitis (AE, = 59) and WHO grade II diffuse astrocytoma (AS, = 79) were divided into training and test sets, using stratified sampling according to MRI scanners. We further included an independent validation set (22 patients with AE and 28 patients with AS). Hyperintensity fluid-attenuated inversion recovery (FLAIR) lesions were segmented for each subject. Ten radiomics and eight spatial distribution features were selected the least absolute shrinkage and selection operator (LASSO), and joint models were constructed by logistic regression for disease classification. Model performance was measured in the test set using the area under the receiver operating characteristic (ROC) curve (AUC). The discrimination performance of the joint model was compared with neuroradiologists.

Results: The joint model achieved better performance (AUC 0.957/0.908, accuracy 0.914/0.840 for test and independent validation sets, respectively) than the radiomics and spatial distribution models. The joint model achieved lower performance than a senior neuroradiologist (AUC 0.917/0.875) but higher performance than a junior neuroradiologist (AUC 0.692/0.745) in the test and independent validation sets.

Conclusion: The joint model of radiomics and spatial distribution from a single FLAIR could effectively classify AE and AS, providing clinical decision support for the differential diagnosis between the two conditions.

Citing Articles

Prediction of Seropositivity in Suspected Autoimmune Encephalitis by Use of Radiomics: A Radiological Proof-of-Concept Study.

Stake J, Spiekers C, Akkurt B, Heindel W, Brix T, Mannil M Diagnostics (Basel). 2024; 14(11).

PMID: 38893597 PMC: 11171889. DOI: 10.3390/diagnostics14111070.


Multiple diffusion metrics in differentiating solid glioma from brain inflammation.

Zhao K, Gao A, Gao E, Qi J, Chen T, Zhao G Front Neurosci. 2024; 17:1320296.

PMID: 38352939 PMC: 10861663. DOI: 10.3389/fnins.2023.1320296.


MRI-based clinical-radiomics nomogram to predict early neurological deterioration in isolated acute pontine infarction: a two-center study in Northeast China.

Wang J, Fu K, Wang Z, Wang N, Wang X, Xu T BMC Neurol. 2024; 24(1):39.

PMID: 38263044 PMC: 10804506. DOI: 10.1186/s12883-024-03533-2.

References
1.
Talathi S, Gupta N, Reddivalla N, Prokhorov S, Gold M . Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. Eur J Paediatr Neurol. 2015; 19(6):722-5. DOI: 10.1016/j.ejpn.2015.07.007. View

2.
Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

3.
Yang L, Li H, Xia W, Quan C, Zhou L, Geng D . Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders. Eur Radiol. 2019; 30(3):1470-1479. DOI: 10.1007/s00330-019-06506-z. View

4.
Jiang C, Kong Z, Zhang Y, Liu S, Liu Z, Chen W . Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology. 2020; 62(7):803-813. DOI: 10.1007/s00234-020-02392-1. View

5.
Wijnenga M, Van der Voort S, French P, Klein S, Dubbink H, Dinjens W . Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neurooncol Adv. 2021; 1(1):vdz001. PMC: 8051437. DOI: 10.1093/noajnl/vdz001. View